

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cryofocus Medtech (Shanghai) Co., Ltd.

康豐生物科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6922)

VOLUNTARY ANNOUNCEMENT

NMPA APPROVAL FOR ANTI-GASTROESOPHAGEAL REFLUX SYSTEM

This announcement is made by Cryofocus Medtech (Shanghai) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders of the Company and potential investors about the latest business development of the Group.

The Company is pleased to announce that on December 15, 2025, the Group’s Anti-Gastroesophageal Reflux System (the “**Anti-Gastroesophageal Reflux System**”), which consists of an anti-gastroesophageal reflux implant device and an esophageal measurement tool, was granted approval by the National Medical Products Administration of the People’s Republic of China (國家藥品監督管理局) (the “**NMPA**”). With the approval of the Anti-Gastroesophageal Reflux System, the Group’s product portfolios become more abundant and diverse.

The Anti-Gastroesophageal Reflux System is a self-developed surgical device indicated for treating gastroesophageal reflux disease (the “**GERD**”) in the magnetic sphincter augmentation procedure by increasing the tension of the lower esophageal sphincter (the “**LES**”) to achieve anti-reflux effect.

The Anti-Gastroesophageal Reflux System works by fixing an implanted device to the LES functional area outside the esophagus, with magnetic beads in the implanted device generating magnetic attraction force to strengthen the tension of LES, thus restoring the anti-reflux function of LES and treating GERD.

THE COMPANY CANNOT GUARANTEE THE FUTURE PROSPECTS OF THE ANTI-GASTROESOPHAGEAL REFLUX SYSTEM. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.

By order of the Board
Cryofocus Medtech (Shanghai) Co., Ltd.
Mr. LI Kejian
Chairman of the Board

Hong Kong, December 16, 2025

As at the date of this announcement, the Board comprises Mr. LI Kejian, Mr. ZHU Jun and Mr. LIU Wei as executive Directors, Mr. LV Shiwen and Mr. ZHAO Chunsheng as non-executive Directors, and Dr. GAO Dayong, Mr. LIANG Hsien Tse Joseph, Dr. QIN Zheng and Dr. HU Henan as independent non-executive Directors.